Testosterone replacement therapy in adolescents and young men

Guidelines for testosterone replacement therapy (TRT) have been well studied and defined in adults, however, this remains less defined for adolescents and young men. There are a variety of conditions in adolescents and young men that necessitate TRT. These conditions range from genetic etiologies such as Kallmann syndrome and Klinefelter syndrome, to acquired causes such as testicular trauma. Conditions can be broadly classified as hypogonadotropic hypogonadism or hypergonadotropic hypogonadism, depending on whether there are concurrently elevated gonadotropins (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)). The decision to initiate TRT in these cases is multifaceted, contributing to the challenge of formulating clear guidelines. In this review, we utilized online sources such as PubMed and Google Scholar to find relevant literature, using key words such as testosterone therapy, adolescents and hormone replacement and hypogonadism in adolescents. This narrative review explores existing literature on TRT in adolescents and young men, encompassing common etiologies of hypogonadism in this population, available TRT therapies, and management and surveillance protocols. Furthermore, it addresses the evolving field of TRT in transgender youth. This study underscores the necessity for additional clinical investigations to explore emerging TRT therapies and establish clear surveillance guidelines tailored to this population.

Testosterone therapy; Hormone replacement; Adolescent male hypogonadism

[1] Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology. 2018; 200: 423–432.

[2] Zhu A, Andino J, Daignault-Newton S, Chopra Z, Sarma A, Dupree JM. What is a normal testosterone level for young men? Rethinking the 300 ng/dL cutoff for testosterone deficiency in men 20–44 years old. The Journal of Urology. 2022; 208: 1295–1302.

[3] Cohen J, Nassau DE, Patel P, Ramasamy R. Low testosterone in adolescents & young adults. Frontiers in Endocrinology. 2020; 10: 916.

[4] Scovell JM, Ramasamy R, Wilken N, Kovac JR, Lipshultz LI. Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dL. BJU International. 2015; 116: 142–146.

[5] Suarez A. MC, Israeli JM, Kresch E, Telis L, Nassau DE. Testosterone therapy in children and adolescents: to whom, how, when? International Journal of Impotence Research. 2022; 34: 652–662.

[6] Cariboni A, Balasubramanian R. Kallmann syndrome and idiopathic hypogonadotropic hypogonadism: the role of semaphorin signaling on GnRH neurons. The Human Hypothalamus: Neuropsychiatric Disorders. 2021; 25: 307–315.

[7] Peterson MD, Belakovskiy A, McGrath R, Yarrow JF. Testosterone deficiency, weakness, and multimorbidity in men. Scientific Reports. 2018; 8: 5897.

[8] Ugo-Neff G, Rizzolo D. Hypogonadism in men. JAAPA. 2022; 35: 28–34.

[9] Stancampiano M, Lucas-Herald A, Russo G, Rogol A, Ahmed SF. Testosterone therapy in adolescent boys: the need for a structured approach. Hormone Research in Paediatrics. 2019; 92: 215–228.

[10] Willemsen LA, Boogers LS, Wiepjes CM, Klink DT, van Trotsenburg ASP, den Heijer M, et al. Just as tall on testosterone; a neutral to positive effect on adult height of GnRHa and testosterone in trans boys. The Journal of Clinical Endocrinology & Metabolism. 2023; 108: 414–421.

[11] Elhadd T, Majzoub A, Wilson C, McCreight L, Mohamed MS, Green FC, et al. Hypergonadotropic hypogonadism and chromosomal aberrations: clinical heterogeneity and implications on the health of elderly men, case series. BMC Endocrine Disorders. 2023; 23: 110.

[12] Skakkebæk A, Wallentin M, Gravholt CH. Klinefelter syndrome or testicular dysgenesis: genetics, endocrinology, and neuropsychology. Handbook of Clinical Neurology. 2021; 93: 445–462.

[13] Millar AC, Faghfoury H, Bieniek JM. Genetics of hypogonadotropic hypogonadism. Translational Andrology and Urology. 2021; 10: 1401–1409.

[14] Cannarella R, Gusmano C, Condorelli RA, Bernini A, Kaftalli J, Maltese PE, et al. Genetic analysis of patients with congenital hypogonadotropic hypogonadism: a case series. International Journal of Molecular Sciences. 2023; 24: 7428.

[15] Amato LGL, Montenegro LR, Lerario AM, Jorge AAL, Guerra Junior G, Schnoll C, et al. New genetic findings in a large cohort of congenital hypogonadotropic hypogonadism. European Journal of Endocrinology. 2019; 181: 103–119.

[16] Spaziani M, Carlomagno F, Tarantino C, Angelini F, Vincenzi L, Gianfrilli D. New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism. Frontiers in Endocrinology. 2023; 14: 1184530.

[17] Kuroda S, Usui K, Sanjo H, Takeshima T, Kawahara T, Uemura H, et al. Genetic disorders and male infertility. Reproductive Medicine and Biology. 2020; 19: 314–322.

[18] Pozza C, Sesti F, Tenuta M, Spaziani M, Tarantino C, Carlomagno F, et al. Testicular dysfunction in 47, XXY boys: when it all begins. A semilongitudinal study. The Journal of Clinical Endocrinology & Metabolism. 2023; 108: 2486–2499.

[19] D’Aurora M, Ferlin A, Di Nicola M, Garolla A, De Toni L, Franchi S, et al. Deregulation of Sertoli and leydig cells function in patients with klinefelter syndrome as evidenced by testis transcriptome analysis. BMC Genomics. 2015; 16: 156.

[20] Aksglaede L, Link K, Giwercman A, Jørgensen N, Skakkebæk NE, Juul A. 47, XXY Klinefelter syndrome: clinical characteristics and age‐specific recommendations for medical management. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2013; 163: 55–63.

[21] Bradshaw AW, Deebel NA, Xu MC, Kogan S, Atala A, Sadri‐Ardekani H. Examining potential mechanisms of testicular fibrosis in Klinefelter syndrome: a review of current understanding. Andrology. 2023; 11: 435–443.

[22] Zitzmann M, Rohayem J. Gonadal dysfunction and beyond: Clinical challenges in children, adolescents, and adults with 47, XXY Klinefelter syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2020; 184: 302–312.

[23] Sizar O, Leslie SW, Schwartz J. Male hypogonadism. StatPearls Publishing: Treasure Island (FL). 2023.

[24] Parmar K, Aggarwal D, Sharma A, Tyagi S, Kumar S, Singh S, et al. Long-term impact of testicular torsion and its salvage on semen parameters and gonadal function. Indian Journal of Urology. 2022; 38: 135.

[25] Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020; 8: 970–987.

[26] Kumar P, Kumar N, Thakur D, Patidar A. Male hypogonadism: symptoms and treatment. Journal of Advanced Pharmaceutical Technology & Research. 2010; 1: 297.

[27] Richard-Eaglin A. Male and female hypogonadism. Nursing Clinics of North America. 2018; 53: 395–405.

[28] Jiménez-Balderas FJ, Tápia-Serrano R, Fonseca ME, Arellano J, Beltrán A, Yáñez P, et al. High frequency of association of rheumatic/autoimmune diseases and untreated male hypogonadism with severe testicular dysfunction. Arthritis Research. 2001; 3: 362–367.

[29] Pivonello R, Menafra D, Riccio E, Garifalos F, Mazzella M, de Angelis C, et al. Metabolic disorders and male hypogonadotropic hypogonadism. Frontiers in Endocrinology. 2019; 10: 345.

[30] Facondo P, Di Lodovico E, Pezzaioli LC, Cappelli C, Ferlin A, Delbarba A. Usefulness of routine assessment of free testosterone for the diagnosis of functional male hypogonadism. The Aging Male. 2022; 25: 72–78.

[31] Pezzaioli LC, Quiros-Roldan E, Paghera S, Porcelli T, Maffezzoni F, Delbarba A, et al. The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience. Infection. 2021; 49: 295–303.

[32] Vogiatzi M, Tursi JP, Jaffe JS, Hobson S, Rogol AD. Testosterone use in adolescent males: current practice and unmet needs. Journal of the Endocrine Society. 2021; 5: bvaa161.

[33] Mason KA, Schoelwer MJ, Rogol AD. Androgens during infancy, childhood, and adolescence: physiology and use in clinical practice. Endocrine Reviews. 2020; 41: bnaa003.

[34] Moskovic DJ, Freundlich RE, Yazdani P, Lipshultz LI, Khera M. Subcutaneous implantable testosterone pellets overcome noncompliance in adolescents with Klinefelter syndrome. Journal of Andrology. 2012; 33: 570–573.

[35] TESTOPEL® (testosterone pellets) C-III. 2024. Available at: https://d1skd172ik98el.cloudfront.net/48a33315-f594-4269-8043-8853d10fb7bf/567f802a-4a33-4fa0-b81c-936bef097178/567f802a-4a33-4fa0-b81c-936bef097178_source__v.pdf (Accessed: 27 March 2024).

[36] Lawaetz JG, Hagen CP, Mieritz MG, Blomberg Jensen M, Petersen JH, Juul A. Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. The Journal of Clinical Endocrinology & Metabolism. 2015; 100: 1376–1385.

[37] Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2018; 103: 1715–1744.

[38] Chioma L, Papucci G, Fintini D, Cappa M. Use of testosterone gel compared to intramuscular formulation for puberty induction in males with constitutional delay of growth and puberty: a preliminary study. Journal of Endocrinological Investigation. 2018; 41: 259–263.

[39] Rogol AD, Swerdloff RS, Reiter EO, Ross JL, ZumBrunnen TL, Pratt GA, et al. A Multicenter, open-label, observational study of testosterone gel (1%) in the treatment of adolescent boys with Klinefelter syndrome or anorchia. Journal of Adolescent Health. 2014; 54: 20–25.

[40] Rogol AD, Tkachenko N, Bryson N. NatestoTM, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016; 4: 46–54.

[41] Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. New England Journal of Medicine. 1988; 319: 1563–1567.

[42] Giri D, Patil P, Blair J, Dharmaraj P, Ramakrishnan R, Das U, et al. Testosterone therapy improves the first year height velocity in adolescent boys with constitutional delay of growth and puberty. International Journal of Endocrinology and Metabolism.2017; 15: e42311.

[43] Diaz A, Figueredo V. Transgender in pediatrics: a narrative review. Pediatric Medicine. 2023; 6: 29.

[44] Carto C, Loloi J, Campbell K, Ramasamy R. Testosterone therapy in men with Klinefelter Syndrome: analysis of a global federated research network. Androgens: Clinical Research and Therapeutics. 2022; 3: 208–212.

[45] Chang S, Skakkebæk A, Davis SM, Gravholt CH. Morbidity in Klinefelter syndrome and the effect of testosterone treatment. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2020; 184: 344–355.

[46] López Krabbe HV, Holm Petersen J, Asserhøj LL, Johannsen TH, Christiansen P, Jensen RB, et al. Reproductive hormones, bone mineral content, body composition, and testosterone therapy in boys and adolescents with Klinefelter syndrome. Endocrine Connections. 2023; 12: e230031.

[47] Zacharin MR, Warne GL. Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Archives of Disease in Childhood. 1997; 76: 495–499.

[48] Contreras MF, Raisingani M, Prasad K, Franklin B, Shah B. Transdermal testosterone gel for induction and continuation of puberty in adolescent boys with hepatic dysfunction. Journal of Pediatric Endocrinology and Metabolism. 2017; 30: 105–109.

[49] Ramasamy R, Masterson TA, Best JC, Bitran J, Ibrahim E, Molina M, et al. Effect of natesto on reproductive hormones, semen parameters and hypogonadal symptoms: a single center, open label, single arm trial. Journal of Urology. 2020; 204: 557–563.

[50] Rambhatla A, Mills JN, Rajfer J. The role of estrogen modulators in male hypogonadism and infertility. Reviews in Urologyvol. 2016; 18: 66–72.

[51] Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. Journal of Urology. 2014; 192: 875–879.

[52] Krzastek SC, Sharma D, Abdullah N, Sultan M, Machen GL, Wenzel JL, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. Journal of Urology. 2019; 202: 1029–1035.

[53] Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective androgen receptor modulators (SARMs)—current knowledge and clinical applications. Sexual Medicine Reviews. 2019; 7: 84–94.

[54] Crawford J, Prado CMM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Current Oncology Reports. 2016; 18: 37.

[55] Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007; 148: 363–373.

[56] Linardi A, Damiani D, Longui CA. The use of aromatase inhibitors in boys with short stature: what to know before prescribing? Archives of Endocrinology and Metabolism. 2017; 61: 391–397.

[57] Varimo T, Huopio H, Kariola L, Tenhola S, Voutilainen R, Toppari J, et al. Letrozole versus testosterone for promotion of endogenous puberty in boys with constitutional delay of growth and puberty: a randomised controlled phase 3 trial. the Lancet Child & Adolescent Health. 2019; 3: 109–120.

[58] Mauras N, Ross J, Mericq V. Management of growth disorders in puberty: GH, GnRHa, and aromatase inhibitors: a clinical review. Endocrine Reviews. 2023; 44: 1–13.

[59] Berger O, Landau Z, Talisman R. Gynecomastia: a systematic review of pharmacological treatments. Frontiers in Pediatrics. 2022; 10: 978311.

[60] McCormack SE, Cousminer DL, Chesi A, Mitchell JA, Roy SM, Kalkwarf HJ, et al. Association between linear growth and bone accrual in a diverse cohort of children and adolescents. JAMA Pediatrics. 2017; 171: e171769.

[61] Mastromattei S, Todisco T, Chioma L, Ubertini G, Pattumelli MG, Fintini D, et al. Efficacy of short-term induction therapy with low-dose testosterone as a diagnostic tool in the workup of delayed growth and puberty in boys. Journal of Endocrinological Investigation. 2022; 45: 2377–2384.

[62] Dunkel L, Prasad R, Martin L, Senniappan S, Butler G, Howard S. UK protocol for induction of puberty with gonadotropins in males with hypogonadotropic hypogonadism. Endocrine Abstracts. 2022; 85.

[63] Gupta S, Deb P, Godbole M. Effects of short-term testosterone replacement on areal bone mineral density and bone turnover in young hypogonadal males. Indian Journal of Endocrinology and Metabolism. 2012; 16: 947.

[64] Corona G, Vena W, Pizzocaro A, Giagulli VA, Francomano D, Rastrelli G, et al. Testosterone supplementation and bone parameters: a systematic review and meta-analysis study. Journal of Endocrinological Investigation. 2022; 45: 911–926.

[65] Kelly BP, Paterson WF, Donaldson MDC. Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone 125 mg per month for 3 months. Clinical Endocrinology. 2003; 58: 267–272.

[66] Stancampiano MR, Lucas-Herald AK, Bryce J, Russo G, Barera G, Balsamo A, et al. Testosterone therapy and its monitoring in adolescent boys with hypogonadism: results of an international survey from the I-DSD registry. Sexual Development. 2021; 15: 236–243.